A Phase 2 Multi-Center, Randomized, Double-Blind, Vehicle-Controlled Ascending Dose Study of SB206 in Children and Adolescents With Molluscum Contagiosum

Trial Profile

A Phase 2 Multi-Center, Randomized, Double-Blind, Vehicle-Controlled Ascending Dose Study of SB206 in Children and Adolescents With Molluscum Contagiosum

Recruiting
Phase of Trial: Phase II

Latest Information Update: 22 Feb 2018

At a glance

  • Drugs Nitric oxide (Primary)
  • Indications Molluscum contagiosum
  • Focus Therapeutic Use
  • Sponsors Novan Inc
  • Most Recent Events

    • 31 Jan 2018 New trial record
    • 25 Jan 2018 According to a Novan Inc media release, the first patient has been dosed in this trial. Top line results are targeted for the fourth quarter of 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top